Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study

BACKGROUND: Current treatment guidelines for immune-mediated diarrhea and colitis (IMDC) recommend steroids as first-line therapy, followed by selective immunosuppressive therapy (SIT) (infliximab or vedolizumab) for refractory cases. We aimed to compare the efficacy of these two SITs and their impa...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Fangwen, Faleck, David, Thomas, Anusha, Harris, Jessica, Satish, Deepika, Wang, Xuemei, Charabaty, Aline, Ernstoff, Marc S, Glitza Oliva, Isabella C, Hanauer, Stephen, McQuade, Jennifer, Obeid, Michel, Shah, Amishi, Richards, David M, Sharon, Elad, Wolchok, Jedd, Thompson, John, Wang, Yinghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601082/
https://www.ncbi.nlm.nih.gov/pubmed/34789551
http://dx.doi.org/10.1136/jitc-2021-003277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601082/
https://www.ncbi.nlm.nih.gov/pubmed/34789551
http://dx.doi.org/10.1136/jitc-2021-003277

Ejemplares similares